Literature DB >> 22826887

Trans-scleral delivery of macromolecules.

Silvia Pescina1, Patrizia Santi, Giulio Ferrari, Sara Nicoli.   

Abstract

Non-invasive drug delivery to the posterior segment of the eye represents an important unmet medical need, and trans-scleral delivery could be an interesting solution. This review analyses the possibility of trans-scleral drug delivery for high molecular weight compounds, such as proteins and genetic material, which currently represent the most innovative and efficacious molecules for the treatment of many diseases of the posterior segment of the eye. The paper reviews all the barriers, both static and dynamic, involved in trans-scleral administration of drugs, trying to elucidate the role of each of them in the specific case of macromolecules. Delivery systems to sustain drug release and enhancing strategies to improve trans-scleral penetration are also described. Finally, the review approaches the use of computational models as a screening tool to evaluate the feasibility of trans-scleral administration for macromolecules.

Mesh:

Substances:

Year:  2011        PMID: 22826887     DOI: 10.4155/tde.11.104

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  3 in total

1.  Melt-Cast Noninvasive Ocular Inserts for Posterior Segment Drug Delivery.

Authors:  Sai Prachetan Balguri; Goutham R Adelli; Akshaya Tatke; Karthik Yadav Janga; Prakash Bhagav; Soumyajit Majumdar
Journal:  J Pharm Sci       Date:  2017-08-01       Impact factor: 3.534

2.  Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules.

Authors:  Sarah Molokhia; Kongnara Papangkorn; Charlotte Butler; John W Higuchi; Balbir Brar; Balamurali Ambati; S Kevin Li; William I Higuchi
Journal:  J Ocul Pharmacol Ther       Date:  2020-03-05       Impact factor: 2.671

Review 3.  Overcoming the cellular barriers and beyond: Recent progress on cell penetrating peptide modified nanomedicine in combating physiological and pathological barriers.

Authors:  Yingke Liu; Zhihe Zhao; Man Li
Journal:  Asian J Pharm Sci       Date:  2022-06-23       Impact factor: 9.273

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.